In patients with AF and COVID-19 who receive DOAC, 30-day mortality risk is similar for nirmatrelvir/ritonavir and RdRp inhibitors.
SAN DIEGO--(BUSINESS WIRE)--TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have collaborated to launch CleanScribe™ RNA Polymerase, a novel enzyme that reduces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results